In order to address this, we used SILAC-based quantitative phosphoproteomics to identify phosphorylation events that changed within the two FGFR2-overexpressing triple-negative breast cancer cell lines MFM223 and SUM52 upon treatment with the FGFR inhibitor SU540232. Here, FGFR2 is linked to triple-negative breast carcinoma.